drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CD19-directed CAR T-cell therapy; genetically modified T cells expressing a CAR with CD3ζ and a costimulatory domain to target and kill CD19+ malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor with CD3ζ signaling and a costimulatory domain. Upon binding CD19 on B cells, the CAR activates T-cell cytotoxicity, cytokine release, and proliferation, resulting in targeted killing and depletion of CD19+ malignant (and normal) B cells.
drug_name
Relmacabtagene autoleucel (Relma-cel)
nct_id_drug_ref
NCT06876688